Skip to main content

Table 2 Clinical characteristics of children aged 6–17 years in urban health facilities in Dire Dawa, 2020 (n = 272)

From: Antiretroviral therapy non-adherence among children living with HIV in Dire Dawa, Eastern Ethiopia: a case-control study

Variables

Total

, N = 272

Cases (n = 78)

Controls (n = 194)

Chi2(df)

p-value

N (%)

N (%)

  

Duration on ART

< 5 years

18 (6.6)

13 (16.7)

5(2.6)

20.11 (2)

< 0.001

5–10 years

93 (34.2)

29 (37.2)

64 (32.9)

  

> 10 years

161 (59.2)

36 (46.2)

125 (64.4)

  

Daily ART dose

One

174 (64.0)

37 (47.4)

137 (70.6)

12.97 (1)

< 0.001

Two

98 (36.0)

41(52.6)

57 (29.4)

  

Base line CD4 Count (cells/mm3)

< 200

14 (5.1)

8 (10.3)

6 (3.1)

8.38 (3)

0.039

200–499

65 (23.9)

18 (23.1)

47 (24.2)

  

>=500

180 (66.2)

46 (59.0)

134 (69.1)

  

Not recorded

13 (4.8)

6 (7.7)

7(3.6)

  

ART regimen

backbone

AZT + 3TC

68 (25.0)

34 (43.6)

34 (17.5)

33.78 (2)

< 0.001

 

TDF + 3TC

161 (59.2)

25 (32.1)

136 (70.1)

  
 

ABC + 3TC

43 (15.8)

19 (24.4)

24 (12.4)

  

Variables

Total

, N = 272

Cases (n = 78)

Controls (n = 194)

Chi2(df)

p-value

N (%)

N (%)

  

Viral load change from baseline values (copies/mL)

Remained ND

91 (33.5)

9 (11.5)

82 (42.3)

28.23 (2)

< 0.001

No change or become < 1000

58 (21.3)

16 (20.5)

42 (21.7)

  

≥ 1000 or increased from ND

123 (45.2)

53 (68.0)

70 (36.1)

  

WHOs clinical stage on admission

Stage-1

217 (79.8)

64(82.1)

153(78.9)

3.32 (2)

0.190

Stage-2

38 (14.0)

7(8.9)

31(15.9)

  

Stage-3

17 (6.2)

7(8.9)

10(5.2)

  

Experienced side effect

Yes

30

9 (11.5)

21 (10.8)

0.029 (1)

0.865

 

No

242

69 (88.5)

173 (89.2)

  
  1. ART = Antiretroviral therapy; chi2 (df) = chi-square degree of freedom; ND = Not detectable; WHO = World Health Organization; AZT = Zidovudine; 3TC = Lamivudine; TDF = Tenofovir; ABC = Abacavir